导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.53% | 2983/4773 |
| 近一周 | -1.91% | 3764/5467 |
| 近一月 | -4.05% | 1517/5421 |
| 近一季 | -2.88% | 1327/5238 |
| 近半年 | -5.89% | 3200/4931 |
| 近一年 | -1.19% | 2805/4400 |
| 近两年 | 30.11% | 2249/2954 |
| 近三年 | 17.17% | 1566/2253 |
| 成立以来 | 132.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.14% 1711/4961 |
-0.18% 3263/5312 |
- - |
- - |
| 2025 | 11.60% 2738/4813 |
2.07% 1476/3635 |
-2.67% 3367/4076 |
10.61% 3266/4524 |
1.56% 1328/4813 |
| 2024 | 15.77% 887/3463 |
5.20% 394/2808 |
0.33% 630/3014 |
13.95% 2070/3129 |
-3.74% 2387/3463 |
| 2023 | -1.27% 499/2656 |
9.69% 395/2280 |
-0.42% 383/2385 |
-3.38% 910/2515 |
-6.45% 1780/2655 |
| 2022 | -18.97% 783/2207 |
-10.89% 449/1919 |
- 1586/2016 |
-12.59% 732/2113 |
4.02% 604/2208 |
| 2021 | -6.96% 1023/1822 |
1.09% 263/1255 |
-4.52% 1262/1330 |
-4.77% 735/1466 |
1.23% 979/1822 |
| 2020 | 19.67% 731/1250 |
-13.16% 922/1028 |
12.64% 677/1067 |
8.56% 705/1164 |
12.69% 443/1184 |
| 2019 | 49.46% 105/1092 |
34.37% 116/754 |
-0.12% 221/804 |
0.75% 470/850 |
10.52% 124/918 |
| 2018 | -27.55% 424/834 |
- - |
- - |
- - |
-10.82% 229/691 |
| 2017 | 30.04% 61/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.20% 243/605 |
- - |
- - |
- - |
- - |
| 2015 | 12.99% 150/575 |
- - |
- - |
- - |
- - |
| 2014 | 42.89% 116/237 |
- - |
- - |
- - |
- - |
| 2013 | -2.44% 72/186 |
- - |
- - |
- - |
- - |
| 2012 | 3.96% 86/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 交银深证300价值ETF联接 VS. 长安沪深300非周期A(740101) |